What is Lecanemab?

1 min read
What is Lecanemab? Blog Image


The drug, Lecanemab, was recently tested on patients with early Alzheimer.

About Lecanemab Drug:

  • Lecanemab is jointly developed by pharma companies Biogen and Eisai.
  • Lecanemab belongs to a class of drugs called monoclonal antibodies. These antibody-mediated drugs target beta amyloid, the protein deposition that is seen in patients with Alzheimer’s disease, and disrupts cells function.


Alzheimer’s disease

  • It is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.  It involves parts of the brain that control thought, memory, and language.
  • It can seriously affect a person’s ability to carry out daily activities.


India’s scenario:

  • In India, only 1 in 10 people with dementia receive any diagnosis, treatment or care for the disease, according to the World Alzheimer’s Report, 2021.


Q1) What are Monoclonal antibodies?

Monoclonal antibodies (mAb or moAb) are identical immunoglobulins, generated from a single B-cell clone which recognize unique epitopes, or binding sites, on a single antigen.

Source: The Hindu